Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 2
2006 2
2007 6
2008 1
2009 2
2010 1
2011 5
2012 8
2013 4
2014 1
2016 4
2017 5
2018 3
2019 4
2020 4
2021 11
2022 2
2023 6
2024 4
2025 7
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.
Cinti F, Morciano C, Guarneri A, Cappannoli L, Sorice G, Gugliandolo S, Capece U, Splendore A, Avolio A, Mezza T, Iozzo P, Pontecorvi A, Calcagni ML, Burzotta F, D'Amario D, Crea F, Leccisotti L, Giaccari A. Cinti F, et al. Among authors: calcagni ml. Cardiovasc Diabetol. 2025 Aug 31;24(1):351. doi: 10.1186/s12933-025-02912-4. Cardiovasc Diabetol. 2025. PMID: 40887630 Free PMC article. Clinical Trial.
Imaging of neuroendocrine tumors.
Rufini V, Calcagni ML, Baum RP. Rufini V, et al. Among authors: calcagni ml. Semin Nucl Med. 2006 Jul;36(3):228-47. doi: 10.1053/j.semnuclmed.2006.03.007. Semin Nucl Med. 2006. PMID: 16762613 Review.
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP. Perrone E, et al. Among authors: calcagni ml. Cancers (Basel). 2025 Sep 19;17(18):3070. doi: 10.3390/cancers17183070. Cancers (Basel). 2025. PMID: 41008911 Free PMC article.
Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.
Perrone E, Giordano A, Calcagni ML, Leccisotti L, Moretti R, Eismant A, Ghai K, Parkar T, Mishra A, Heidenreich A, Wirtz RM, Müller J, Greifenstein L, Baum RP. Perrone E, et al. Among authors: calcagni ml. Cancers (Basel). 2025 Jan 26;17(3):405. doi: 10.3390/cancers17030405. Cancers (Basel). 2025. PMID: 39941774 Free PMC article.
Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters.
Taralli S, Orlandi A, Pafundi PC, Tempesta V, Di Leone A, Pontolillo L, Scardina L, Lorusso M, Paris I, Calcagni ML. Taralli S, et al. Among authors: calcagni ml. Radiol Med. 2025 Mar;130(3):422-437. doi: 10.1007/s11547-025-01961-9. Epub 2025 Feb 12. Radiol Med. 2025. PMID: 39937369
Intranasal human-recombinant NGF administration improves outcome in children with post-traumatic unresponsive wakefulness syndrome.
Gatto A, Capossela L, Conti G, Eftimiadi G, Ferretti S, Manni L, Curatola A, Graglia B, Di Sarno L, Calcagni ML, Di Giuda D, Cecere S, Romeo DM, Soligo M, Picconi E, Piastra M, Della Marca G, Staccioli S, Ruggiero A, Cocciolillo F, Pulitanò S, Chiaretti A. Gatto A, et al. Among authors: calcagni ml. Biol Direct. 2023 Oct 3;18(1):61. doi: 10.1186/s13062-023-00418-1. Biol Direct. 2023. PMID: 37789391 Free PMC article.
80 results